<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02505854</url>
  </required_header>
  <id_info>
    <org_study_id>CEP 104-14</org_study_id>
    <nct_id>NCT02505854</nct_id>
  </id_info>
  <brief_title>Influence of Probiotic and Symbiotic in Body Weight, Blood Sugar and Lipemia of Obese Women</brief_title>
  <official_title>Influence of Probiotic and Symbiotic in Body Weight, Blood Sugar and Lipemia of Obese Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal do Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rio de Janeiro State Research Supporting Foundation (FAPERJ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Federal do Rio de Janeiro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether gut microbiota modulation by probiotic and
      symbiotic contribute with weight loss and improvement of metabolic parameters in women with
      obesity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will evaluate the effects of probiotic and symbiotic on weigh loss, blood glucose, lipid
      profile, metabolomic profile, and gut microbiota composition variables in women with obesity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">November 2018</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the effect of probiotic and symbiotic on weight loss of women obese</measure>
    <time_frame>Baseline and 60 days and 15 days after the end of the intervention</time_frame>
    <description>Determine and evaluate change in body weight and body mass index after intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of probiotic and symbiotic on blood glucose</measure>
    <time_frame>Baseline, 60 days and 15 days after the end of the intervention</time_frame>
    <description>Determine and comparing the blood glucose in plasma before and after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of probiotic and symbiotic on insulin resistance</measure>
    <time_frame>Baseline and 60 days</time_frame>
    <description>Compare insulin resistance through HOMA-IR calculation before and after intervention and evaluate whether the intervention improvement in this parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of probiotic and symbiotic on lipid profile</measure>
    <time_frame>Baseline and 60 days</time_frame>
    <description>Compare lipid profile (total cholesterol, low-density lipoprotein, high-density lipoprotein, very low-density lipoprotein, triglyceride) in serum of blood before and after intervention and evaluate whether the intervention improvement in this parameter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect probiotic and symbiotic on blood pressure</measure>
    <time_frame>Baseline,60 days and 15 days after intervention conclusion</time_frame>
    <description>Determine blood pressure and evaluate whether the intervention improvement blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of probiotic and symbiotic on gut microbiota composition</measure>
    <time_frame>Baseline, 60 days and 15 days after intervention conclusion</time_frame>
    <description>Determine and comparing the amount filos (Fimicutes, Bacteroidetes, Actinobacteria, Verrucomicrobia e Proteobacteria) in gut microbiota and whether the change in microbiota composition continue after stop probiotic and symbiotic intake</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of probiotic and symbiotic on stool consitency by Bristol scale</measure>
    <time_frame>Baseline,60 days and 15 days after intervention conclusion</time_frame>
    <description>Determine and comparing the stool consistency by Bristol scale. The Bristol scale is composed of 7 different stool consistency, being 1 and 2 lumpy, 3 and 4 normal, 5 to 7 loose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of probiotic and symbiotic on gastrointestinal symptons</measure>
    <time_frame>Baseline,60 days and 15 days after intervention conclusion</time_frame>
    <description>Evaluate the presence of gastrointestinal symptoms related to the probiotic and symbiotic. The gastrointestinal symptoms analyzed were abdominal pains, abdominal distension and abdominal discomfort, flatus, borborygmus using the Likert scale of 5 point, which 0 is absence of symptom and 4 is every day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of probiotic and symbiotic on metabolomic profile</measure>
    <time_frame>Baseline and 60 days</time_frame>
    <description>Determine and comparing change in metabolomic profile before and after intervention. The metabolomic profile was evaluated in the serum of blood Bruker DRX 500 MHz equipment (Bruker Spectrospin, Karlsruhe, Germany) generating hydrogen isotope 1 (1H)-NMR spectra, that was compared to database Human Metabolome Data Base.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache with 5 g of maltodextrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbiotic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache with 5 g of fructooligosaccharide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Hypocaloric diet associated with capsule containing 50g of gelatin and sache with 5 g of maltodextrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of maltodextrin</description>
    <arm_group_label>Probiotic</arm_group_label>
    <other_name>Bifidobacterium lactis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Symbiotic</intervention_name>
    <description>Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of fructooligosaccharide</description>
    <arm_group_label>Symbiotic</arm_group_label>
    <other_name>Bifidobacterium lactis and fructooligosaccharide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Hypocaloric diet associated with capsule containing 50g of gelatin and sache of maltodextrin</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Gelatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women;

          -  Adult;

          -  Obese (BMI between 30 and 39,9 Kg/m²).

        Exclusion Criteria:

          -  Pregnancy or nursing;

          -  Smokers;

          -  Drinkers;

          -  Use of drug or phytotherapic;

          -  Diagnosis of any cronic disease;

          -  Daily consumption of yogurt.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Louise C Oliveira, MD student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal do Rio de Janeiro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Louise Crovesy de Oliveira</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.nutricao.ufrj.br/</url>
    <description>Institute of Nutrition Josué de Castro</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>July 16, 2015</study_first_submitted>
  <study_first_submitted_qc>July 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2015</study_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal do Rio de Janeiro</investigator_affiliation>
    <investigator_full_name>Louise Crovesy de Oliveira</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Symbiotic</keyword>
  <keyword>Weight loss</keyword>
  <keyword>Gut microbiota</keyword>
  <keyword>Bifidobacterium lactis</keyword>
  <keyword>Fructooligosaccharide</keyword>
  <keyword>Blood sugar</keyword>
  <keyword>Lipemia</keyword>
  <keyword>Metabolome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Body Weight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

